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ABSTRACT: Multidrug membrane transporters (eﬄux pumps) are responsible
for multidrug resistance (MDR) and the low eﬃcacy of therapeutic drugs. Noble
metal nanoparticles (NPs) possess a high surface-area-to-volume ratio and sizedependent plasmonic optical properties, enabling them to serve both as imaging
probes to study sized-dependent MDR and as potential drug carriers to
circumvent MDR and enhance therapeutic eﬃcacy. To this end, in this study, we
synthesized three diﬀerent sizes of silver nanoparticles (Ag NPs), 2.4 ± 0.7, 13.0
± 3.1, and 92.6 ± 4.4 nm, functionalized their surface with a monolayer of 11amino-1-undecanethiol (AUT), and covalently conjugated them with antibiotics
(oﬂoxacin, Oﬂx) to prepare antibiotic drug nanocarriers with conjugation ratios
of 8.6 × 102, 9.4 × 103, and 6.5 × 105 Oﬂx molecules per NP, respectively. We
puriﬁed and characterized the nanocarriers and developed cell culture medium in
which the cells grew normally and the nanocarriers were stable (non-aggregated),
to quantitatively study the size, dose, and eﬄux pump (MexAB-OprM)
dependent inhibitory eﬀect of the nanocarriers against two strains of Pseudomonas aeruginosa, WT (normal expression of
MexAB-OprM) and ΔABM (deletion of MexAB-OprM). We found that the inhibitory eﬀect of these nanocarriers highly
depended on the sizes of NPs, the doses of antibiotic, and the expression of MexAB-OprM. The same amount of Oﬂx on the
largest nanocarriers (92.6 ± 4.4 nm) showed the highest inhibitory eﬀect (the lowest minimal inhibitory concentration) against
P. aeruginosa. Surprisingly, the smallest nanocarriers (2.4 ± 0.7 nm) exhibited a lower inhibitory eﬀect than free Oﬂx. The results
suggest that size-dependent multivalent eﬀects, the distribution and localization of Oﬂx (pharmacodynamics), and the eﬄux of
Oﬂx all play a role in the inhibitory eﬀects. Control experiments using three sizes of AgMUNH2 NPs (absence of Oﬂx) showed
that these NPs do not exhibit any signiﬁcant inhibitory activity toward both strains. These new ﬁndings demonstrate the need for
and possibility of designing optimal sized antibiotic nanocarriers to achieve the highest eﬃcacy against P. aeruginosa.

■

INTRODUCTION
All living organisms are equipped with multi-substrate extrusion
systems (membrane transporters or eﬄux pumps) to selectively
extrude a wide range of substrates out of live cells.1,2 Such selfprotective eﬄux machinery resists the accumulation of
structurally and functionally unrelated noxious compounds
inside the cells and causes multidrug resistance (MDR) and low
eﬃcacy of therapeutic drugs (e.g., antibiotics).3−7 MDR is
responsible for the creation of superbugs and the urgent need
to develop new classes of antibiotics against bacterial
pathogens.7,8 Multidrug membrane transporters have been
identiﬁed as targets to increase the eﬃcacy of therapeutic drugs
and the eﬀectiveness of treatment.7−9 However, despite
extensive studies over decades, the molecular mechanisms of
MDR and the eﬄux functions of multidrug membrane
transporters remain elusive.4,7,8,10,11
Pseudomonas aeruginosa (a ubiquitous Gram-negative bacterium) has become one of the major opportunistic human
pathogens and a leading cause of nosocomial infections.10,12−15
P. aeruginosa possesses several multidrug membrane transporters (eﬄux pumps).16−20 These multidrug membrane
© 2018 American Chemical Society

transporters can selectively extrude a wide variety of structurally
and functionally unrelated antibiotics out of the bacterial cells,
which causes MDR and diﬃculty in treating infections.4,10,11,20,21 For example, MexAB-OprM is the primary
membrane transporter found in wild-type (WT) P. aeruginosa,
and it consists of two inner membrane proteins (MexA and
MexB) and one outer membrane protein (OprM).22−24 The
MexAB-OprM transporter of P. aeruginosa can extrude an array
of antibiotics (e.g., oﬂoxacin, azthreonam, chloramphenicol, and
gentamicin) out of these cells, leading to a lower accumulation
of antibiotics inside the cells and a higher minimal inhibitory
concentration (MIC) against P. aeruginosa.25 Notably, the sizes,
structures, and chemical properties of antibiotics (pump
substrates) vary drastically.
Nanomaterials possess distinctive physiochemical properties,
such as high surface-to-volume ratios and small sizes. Studies
have shown that these distinctive properties could enable
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nanomaterials to serve as drug carriers to increase the payload
of therapeutic agents and hence enhance the eﬃcacy of
localization for targeted therapy.26−28 However, systematic and
quantitative studies of the dependence of eﬃcacy of drug
nanocarrier on their physicochemical properties (e.g., sizes) and
their underlying molecular mechanisms remain largely unexplored. Furthermore, it remains very challenging to characterize
the physicochemical properties of individual nanocarriers in situ
in real time at single NP resolution. Moreover, current studies
have primarily focused on polymer-based nanocarriers (e.g.,
vesicles) for treating eukaryotic cells, with only few studies
examining noble metal NP-based antibiotic nanocarriers for
inhibiting the growth of bacteria.26−29
Noble metal NPs (e.g., Ag NPs) exhibit sized-dependent
plasmonic optical properties, exceptionally high Rayleigh
scattering, and photostability (non-photobleaching and nonblinking).29−36 We have directly imaged and characterized
single noble metal NPs (Ag or Au NPs) in situ in real time
using dark-ﬁeld optical microscopy and spectroscopy
(DFOMS).34,35,37−39 We have used size-dependent localized
surface plasmon resonance (LSPR) spectra of single NPs to
determine the sizes of individual NPs in solution, single live
cells, and embryos in situ in real time, and we have directly
measured the sizes of single NPs as they are transported in and
out of single live cells in real time.29,32−36,40−43 We have
demonstrated that Ag and Au NPs can serve as photostable
nanophotonic optical probes for sensing and imaging single
molecules and dynamics events of interest in single live cells
and embryos over time.34,36−41,43−47 For instance, we have used
the intrinsic optical properties of single Ag and Au NPs to study
the size-dependent transport dynamics of single membrane
transporters and the size-dependent permeability of cellular
membranes of single live cells induced by antibiotics (e.g.,
aztreonam, chloramphenicol) at nanometer spatial resolution
and millisecond temporal resolution.36,40,41,43
In this study, we synthesized, puriﬁed, and characterized
three diﬀerent sizes of Ag NP-based antibiotic nanocarriers (2.4
± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm). We quantitatively
studied the size, dose, and eﬄux pump (MexAB-OprM)
dependent inhibitory eﬀects (susceptibility) of the nanocarriers
against two strains of P. aeruginosa, WT (normal expression of
MexAB-OprM) and ΔABM (deletion of MexAB-OprM),
aiming to study not only the dependence of the therapeutic
eﬀects of antibiotics on the sizes of the nanocarriers but also the
dependence of the eﬄux function of the MexAB-OprM
multidrug membrane transporter of P. aeruginosa on the sizes
of the nanocarriers. We used single Ag NPs both as antibiotic
nanocarriers and as imaging probes to study their MDR
dependent therapeutic eﬀects, aiming to rationally design
nanocarriers that not only can increase the local payload of
therapeutic agents to target bacteria, but also can evade
multidrug eﬄux pumps and circumvent MDR, thus achieving
higher eﬃcacy and lower therapeutic side eﬀects. To our
knowledge, drug nanocarriers have not yet been reported for
the study of MDR and the eﬄux function of a multidrug
membrane transporter in bacteria.

Figure 1. Characterization of sizes, shapes, and plasmonic optical
properties of three diﬀerent sized Ag NPs. (A) HRTEM images of
single Ag NPs and (B) histograms of their size distributions show
nearly spherical shaped NPs with average diameters of (a) 2.4 ± 0.7,
(b) 13.0 ± 3.1, and (c) 92.6 ± 4.4 nm. (C) UV−vis absorption spectra
of the NPs in DI water show the peak absorption (full width at halfmaximum), λmax (fwhm), at (a) 392 (57), (b) 395 (59), and (c) 450
nm with a shoulder peak of 390 nm, respectively.

(Figure 1B: a−c) of the three diﬀerent NP samples show nearly
spherical shaped NPs with diameters of 2.4 ± 0.7, 13.0 ± 3.1,
and 92.6 ± 4.4 nm, respectively. Notably, the shapes of the
smallest NPs are the closest to spherical. In contrast, the shapes
of the largest NPs are polygonal (the least spherical). The
diameters of oval and irregular shaped NPs were determined by
averaging the length and width of the NPs.
We characterized the plasmonic absorption and scattering of
Ag NP solutions using UV−vis absorption spectroscopy. UV−
vis absorption spectra of three diﬀerent sized NPs with
diameters of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm show
that their peak wavelengths with full width at half-maximum,
λmax (fwhm), are 392 (57), 395 (59), and 450 (182) nm,
respectively. We did not observe any shoulder peak for NPs
with diameters of either 2.4 ± 0.7 or 13.0 ± 3.1 nm, further
demonstrating that they are nearly spherical. In contrast, we
observed one shoulder peak at 390 nm for the 92.6 ± 4.4 nm
diameter NPs, which is most likely attributed to the in-plane
quadrupole resonance of the NPs generated by transverse
collective oscillation of the surface electrons between the edges
of the NPs. Notably, the TEM images of the NPs (Figure 1A:
c) indeed show that they are polygonal with sharp edges.
Synthesis and Characterization of Antibiotic Nanocarriers (AgMUNH-Oﬂx NPs). We functionalized the well
puriﬁed and characterized Ag NPs with a monolayer of 11amino-1-undecanethiol (AUT) by replacing the citrate

■

RESULTS AND DISCUSSION
Synthesis and Characterization of Three Diﬀerent
Sized Ag NPs. We synthesized and puriﬁed three diﬀerent
sized Ag NPs, as described in Materials and Methods and as
reported previously by us.32,37,38,47,48 Representative TEM
images (Figure 1A: a−c) and histograms of size distribution
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Figure 2. Schematic illustration of synthesis of three diﬀerent sized antibiotic nanocarriers. The surfaces of (A) 2.4 ± 0.7, (B) 13.0 ± 3.1 and (C)
92.6 ± 4.4 nm Ag NPs were functionalized with a monolayer of AUT using the interaction of the thiol groups (−SH) of AUT with the surface of Ag
NPs to prepare AgMUNH2 NPs. The amine group of AUT attached onto the surface of Ag NPs was then conjugated with the carboxyl group of the
Oﬂx via a peptide bond using EDC and sulfo-NHS as mediators to prepare AgMUNH-Oﬂx NPs (antibiotic nanocarriers).

nanocarriers (AgMUNH-Oﬂx NPs). We subtracted the
absorption spectrum of AgMUNH2 NPs from that of
AgMUNH-Oﬂx NPs and determined the concentration of
Oﬂx covalently attached onto the nanocarriers using the
absorbance at 288 nm. We used the plasmonic peak absorbance
of NPs in the same nanocarriers to determine the concentration
of NPs. We divided the Oﬂx concentration of the nanocarrier
by the NP concentration of the same nanocarrier solution to
quantitatively characterize the conjugation ratio of Oﬂx
molecules to NPs, showing 8.6 × 102 Oﬂx molecules/NP for
the 2.4 ± 0.7 nm Ag NPs. Using a close-packed model with the
footprint of each AUT molecule of 0.214 × 0.214 nm2 on the
surface of the NP,38 we found that the smooth surface area of a
perfectly spherical NP with a diameter of 2.4 nm could only
accommodate 395 Oﬂx molecules/NP. The 2-fold higher
payload of 8.6 × 102 Oﬂx molecules/NP could be attributed to
the rough surface and irregular shape of the NPs.
The absorption spectrum of the 13.0 ± 3.1 nm Ag NPs
(Figure 3B: a) shows a plasmonic absorption peak wavelength
at 399 nm and a fwhm of 58 nm. After their surface was
functionalized with a monolayer of AUT, their plasmonic
absorption spectrum (Figure 3B: b) red-shifted and showed a
peak wavelength of 413 nm and a fwhm of 132 nm. After the
AgMUNH2 NPs were conjugated with Oﬂx, the plasmonic
absorption spectrum of AgMUNH-Oﬂx NPs (nanocarriers)
exhibited both the distinctive absorption peak wavelengths of
Oﬂx at 288 and 331 nm as well as the plasmonic peak

molecules electrostatically adsorbed on the surface of the NPs
with AUT via the interaction of thiol groups of AUT with the
NPs to prepare AgMUNH2 NPs, as presented in the Materials
and Methods and Figure 2. We washed the AgMUNH2 NPs
thoroughly with nanopure water to remove excess AUT using
centrifugation. We then covalently conjugated the amine
groups of each size of AgMUNH2 NPs with the carboxyl
group of oﬂoxacin (Oﬂx) via a peptide bond using a two-step
method with EDC and sulfo-NHS as mediators to prepare
antibiotic nanocarriers (AgMUNH-Oﬂx NPs), as illustrated in
Figure 2.
We puriﬁed the drug nanocarriers (AgMUNH-Oﬂx NPs) by
thoroughly washing them with deionized (DI) water, and we
characterized the conjugation ratios of Oﬂx molecules to the
NPs using UV−vis absorption spectroscopy, as shown in Figure
3 and Table 1. The absorption spectrum of 2.4 ± 0.7 nm Ag
NPs (Figure 3A: a) shows a plasmonic absorption peak
wavelength of 390 nm with a fwhm of 55 nm. After the surface
of the NPs was functionalized with a monolayer of AUT, the
refractivity of the NPs decreased and their dielectric constant
increased, leading to a red-shifted and broader plasmonic
absorption spectrum. Thus, the plasmonic absorption spectrum
of AgMUNH2 NPs (Figure 3A: b) shows a peak wavelength of
413 nm and a fwhm of 132 nm. Upon conjugation of Oﬂx with
the AgMUNH2 NPs, we observed both the distinctive
absorption peak wavelengths of Oﬂx at 288 and 331 nm and
the plasmonic peak absorption of the NPs at 416 nm for the
1233
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absorption of NPs at 418 nm for the nanocarriers (AgMUNHOﬂx NPs). Using the same approaches as described above, we
quantitatively characterized the conjugation ratio of Oﬂx
molecules to NPs as 9.4 × 103 Oﬂx molecules/NP for the
13.0 ± 3.1 nm NPs, which is nearly equal to the maximum
number of AUT molecules (1.2 × 104 molecules) that could be
closely packed on the surface of a spherical NP with a diameter
of 13 nm, as determined by the close-packed model.
The absorption spectrum of the 92.6 ± 4.4 nm Ag NPs
(Figure 3C: a) shows a plasmonic absorption peak wavelength
at 450 nm. After their surface was functionalized with a
monolayer of AUT, the peak wavelength of the plasmonic
absorption spectrum red-shifted to 453 nm (Figure 3C: b).
Upon conjugation of the AgMUNH2 NPs with Oﬂx, the
plasmonic absorption spectrum of AgMUNH-Oﬂx NPs
exhibited both the distinctive absorption peak wavelengths of
Oﬂx at 288 and 331 nm as well as a further red-shifted
plasmonic peak absorption of the NPs to 500 nm. Using the
same approaches described above, we quantitatively characterized the conjugation ratio of Oﬂx to the NPs as 6.5 × 105
Oﬂx molecules/NP for the 92.6 ± 4.4 nm NPs, which is
approximately equal to the maximum number of AUT
molecules (5.9 × 105 molecules) that could be closely packed
on the surface of a perfectly spherical NP with a diameter of
92.6 nm, as determined by the close-packed model.
Stability of Drug Nanocarriers (AgMUNH-Oﬂx NPs) in
Cell Culture Medium. In order to study the dependence of
the inhibitory eﬀects of these antibiotic nanocarriers against P.
aeruginosa on the sizes of NPs and doses of antibiotic, it is
crucial that the nanocarriers remain stable (non-aggregated) in
cell culture medium and that their sizes and doses remain
unchanged over the entire duration of the cell culture
experiment. If the nanocarriers aggregate in the cell culture
medium, then their sizes and doses would change over time,
making a study of their size and dose dependent inhibitory
eﬀects unreliable.
Therefore, we ﬁrst characterized the stability (nonaggregation) of each size of drug nanocarriers (AgMUNHOﬂx NPs) in a commonly used standard LB medium (1%
tryptone, 0.5% yeast extract, and 0.5% NaCl in DI water, pH =
7.2) over 24 h using UV−vis absorption spectra. Unfortunately,
none of the nanocarriers at the desired concentration were
stable in this standard medium.
We then reduced the concentration of NaCl to 0.1% and
characterized the stability (non-aggregation) of the drug
nanocarriers in the modiﬁed medium (1% tryptone, 0.5%
yeast extract, and 0.1% NaCl in DI water, pH = 7.2) over 24 h
using UV−vis absorption spectroscopy. The results in Figure 4
show that the absorption spectra of the nanocarriers remain
unchanged over 24 h, indicating that the nanocarriers with Ag
NP diameters of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm and
concentrations of 6.0 nM, 0.8 nM, and 7 pM were stable (nonaggregated) in the modiﬁed medium over 24 h, respectively.
Suitability of the Modiﬁed LB Medium for Cell
Culture. To ensure that the modiﬁed cell culture medium is
well suited for culturing healthy cells as their standard cell
culture medium, we pre-cultured the cells (WT, ΔABM, and
nalB-1) in the standard medium for 12 h. We then cultured the
pre-cultured cells in the standard medium and the modiﬁed
medium and measured the growth curves of the cells over time.
The results show that the growth curves of the cells cultured in
the standard medium (Figure S1-a) and the modiﬁed medium

Figure 3. Characterization of conjugation ratios of Oﬂx molecules with
NPs for three diﬀerent sized Ag NPs using UV−vis absorption
spectroscopy. (A) UV−vis absorption spectra of (a) 2.4 ± 0.7 nm Ag
NPs, (b) AgMUNH2 NPs, and (c) AgMUNH-Oﬂx NPs show
plasmonic absorption peak wavelengths (λmax) of the NPs at 392, 413,
and 416 nm, respectively. (B) UV−vis absorption spectra of (a) 13.0 ±
3.1 nm Ag NPs, (b) AgMUNH2 NPs, and (c) AgMUNH-Oﬂx NPs
show plasmonic absorption λmax of the NPs at 394, 414, and 418 nm,
respectively. (C) UV−vis absorption spectra of (a) 92.6 ± 4.4 nm Ag
NPs, (b) AgMUNH2 NPs, and (c) AgMUNH-Oﬂx NPs show
plasmonic absorption λmax of the NPs at 450, 453, and 486 nm,
respectively. Note that signature absorption λmax of Oﬂx at 288 and
331 nm were observed only in (c) for the three sized nanocarriers,
showing the conjugation of Oﬂx with the NPs.

Table 1. Determination of the Conjugation Ratios of
Oﬂoxacin (Oﬂx) Molecules per NP for Three Diﬀerent Sized
Drug Nanocarriers
NP diameter (nm)

CNPsa (nM)

COflxb (μM)

ROflx/NPc

2.4 ± 0.7
13.0 ± 3.1
92.6 ± 4.4

50
3.3
0.030

43.2
31.1
19.4

8.6 × 102
9.4 × 103
6.5 × 105

a

Plasmonic absorbance of the drug nanocarriers (AgMUNH-Oﬂx
NPs) at λmax of 416, 418, and 486 nm was used to determine the
concentration of the 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm NPs,
respectively. bCOflx was determined by subtracting the UV−vis
absorption spectra of AgMUNH2 NPs from that of AgMUNH-Oﬂx
NPs and dividing the peak absorbance of the subtracted UV−vis
spectra at 288 nm by the molar absorptivity (ε288nm) of Oﬂx, 7.8 × 103
M−1 cm−1. cConjugation ratio of the number of Oﬂx molecules per NP
was calculated by dividing the concentration of Oﬂx by the
concentration of NPs for the same solution of AgMUNH-Oﬂx NPs
for the 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm NPs, respectively.
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with WT cells (normal expression of MexAB-OprM) increases
slightly over time (Figure S3-b) and the ﬂuorescence intensity
of EtBr incubated with nalB-1 cells (overexpression of MexABOprM) remains essentially unchanged over time (Figure S3-c).
These results show the high dependence of the accumulation
kinetics of intracellular EtBr on the expression level of MexABOprM. The cells (ΔABM) with deletion of MexAB-OprM
exhibit the highest accumulation rate of intracellular EtBr, and
the cells (nalB-1) with over-expression of MexAB-OprM show
the lowest accumulation rate of intracellular EtBr, indicating
that MexAB-OprM extrudes EtBr out of the cells, which leads
to the lowest accumulation of intracellular EtBr in nalB-1 cells.
The accumulation rate of EtBr incubated with cells cultured in
either the standard medium (Figure S3-A) or the modiﬁed
medium (Figure S3-B) is the same, further demonstrating that
the modiﬁed medium is well suited to culture healthy cells with
a fully functioning eﬄux pump (MexAB-OprM).
Dose, Size, and MexAB-OprM Dependent Inhibitory
Eﬀects of Drug Nanocarriers (AgMUNH-Oﬂx NPs). We
cultured the cells (WT or ΔABM) in the modiﬁed medium
containing a dilution series of Oﬂx alone, each given sized drug
nanocarrier (AgMUNH-Oﬂx NPs), and AgMUNH2 NPs
(absence of Oﬂx, control experiments) by inoculating 104
pre-cultured cells into the medium and vigorously shaking
the solution (200 rpm, 37 °C) over 17 h.
The dilution series contains 0, 0.20, 0.40, 0.60, 0.80, 1.08,
1.62, and 2.16 μM free Oﬂx (Figure 5A) or Oﬂx conjugated
with the NPs (AgMUNH-Oﬂx NPs) for WT cells (Figure 5B−
D: b−h), which is correlated with the concentration of the
nanocarrier (NP concentration) as follows: (Figure 5B: b−h)
0.23, 0.463, 0.695, 0.917, 1.25, 1.88, and 2.50 nM for 2.4 ± 0.7
nm NPs with a conjugation ratio of 8.6 × 102 Oﬂx molecules
per NP; (Figure 5C: b−h) 2.12 × 10−2, 4.24 × 10−2, 6.36 ×
10−2, 8.48 × 10−2, 0.114, 0.172, and 0.229 nM for 13.0 ± 3.1
nm NPs with a conjugation ratio of 9.4 × 103 Oﬂx molecules
per NP; and (Figure 5D: b−h) 0.309, 0.618, 0.926, 1.24, 1.67,
2.50, and 3.34 pM for 92.6 ± 4.4 nm NPs with a conjugation
ratio of 6.5 × 105 Oﬂx molecules per NP. The control
experiments include the medium alone (absence of cells, Figure
5A−D: a) and WT cells cultured under the same conditions
and at the same time in the medium containing 2.50 nM, 0.229
nM, or 3.34 pM AgMUNH2 NPs (in the absence of Oﬂx,
Figure 5B−D: i) for the 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm
NPs, respectively.
The dilution series contains 0, 0.020, 0.040, 0.060, 0.080,
0.11, 0.14, 0.28 μM free Oﬂx (Figure 5E) or Oﬂx conjugated
with the NPs (AgMUNH-Oﬂx NPs) (Figure 5F−H) for
ΔABM, which is correlated with the concentration of the
nanocarrier (NP concentration) as follows: (Figure 5F: k−q)
2.32 × 10−2, 4.63 × 10−2, 6.95 × 10−2, 9.27 × 10−2, 0.127,
0.162, and 0.324 nM for 2.4 ± 0.7 nm NPs with a conjugation
ratio of 8.6 × 102 Oﬂx molecules per NP; (Figure 5G: k−q)
2.12 × 10−3, 4.24 × 10−3, 6.36 × 10−3, 8.48 × 10−3, 1.48 × 10−2,
and 2.97 × 10−2 nM for 13.0 ± 3.1 nm NPs with a conjugation
ratio of 9.4 × 103 Oﬂx molecules per NP; and (Figure 5H: k−
q) 3.09 × 10−2, 6.18 × 10−2, 9.26 × 10−2, 0.124, 0.170, 0.216,
and 0.432 pM for 92.6 ± 4.4 nm NPs with a conjugation ratio
of 6.5 × 105 Oﬂx molecules per NP. The control experiments
include the medium alone (absence of cells, Figure 5E−H: j)
and ΔABM cells cultured under the same conditions and at the
same time in the medium containing 0.324 nM, 2.97 × 10−2
nM, or 0.432 pM AgMUNH2 NPs (in the absence of Oﬂx,

Figure 4. Characterization of the stability (non-aggregation) of three
sized antibiotic nanocarriers (AgMUNH-Oﬂx NPs) in the modiﬁed LB
medium using UV−vis absorption spectroscopy. The UV−vis
absorption spectra of 6 nM, 0.8 nM, and 7 pM AgMUNH-Oﬂx NPs
for the Ag NPs with diameters of (A) 2.4 ± 0.7, (B) 13.0 ± 3.1, and
(C) 92.6 ± 4.4 nm in the modiﬁed LB medium at (a) 0 and (b) 24 h
remain essentially unchanged over time, which indicates that the
nanocarriers are stable (non-aggregated) in this medium over 24 h.

(Figure S1-b) are the same, which demonstrates that the
modiﬁed medium is well suited for culturing these cells.
We further characterized the viability of the cells that had
been cultured in the standard and modiﬁed medium over 12 h
using live/dead BacLight assay. Representative optical and
ﬂuorescence images of the cultured cells show that more than
99% of the cells cultured in the standard and modiﬁed LB
medium over time exhibit SYTO9 green ﬂuorescence and they
are viable (Figure S2). The results further demonstrate that the
modiﬁed medium can be used to replace the standard medium
to culture these cells.
Moreover, we characterized the eﬄux function of MexABOprM by probing the MexAB-OprM dependent accumulation
kinetics of intracellular ethidium bromide (EtBr) in live cells
(WT, ΔABM, and nalB-1). The experiments were conducted in
parallel. EtBr shows a low ﬂuorescence intensity outside the
cells. As EtBr enters the cells and intercalates with DNA, its
ﬂuorescence intensity increases ∼10 times.49 Thus, the
ﬂuorescence intensity of EtBr has been widely used to
characterize the eﬄux function of multidrug membrane
transporters in live cells in real time using ﬂuorescence
spectroscopy.33,45,50−54 The results in Figure S3 show that
the ﬂuorescence intensity of EtBr incubated with ΔABM cells
(deletion of MexAB-OprM) rapidly increases with time (Figure
S3-a), whereas the ﬂuorescence intensity of EtBr incubated
1235
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Figure 5. Study of the concentration, size, and MexAB-OprM dependent inhibitory eﬀects of antibiotic nanocarriers (AgMUNH-Oﬂx NPs) on the
growth of (A−D) WT and (E−H) ΔABM cells. (A−D) Images of the modiﬁed LB medium cultured (a) without cells (blank control) and with WT
cells containing (b−i) 0, 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 μM (A) unconjugated free Oﬂx alone and (b−h) 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 μM Oﬂx
conjugated with Ag NPs of (B) 2.4 ± 0.7, (C) 13.0 ± 3.1, and (D) 92.6 ± 4.4 nm in diameter, respectively. (E−H) Images of the modiﬁed LB
medium cultured (j) without cells (blank control) and with ΔABM cells containing (k−r) 0, 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, and 0.27 μM (E)
unconjugated free Oﬂx alone and (k−r) 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, and 0.27 μM Oﬂx conjugated with the Ag NPs of (F) 2.4 ± 0.7, (G) 13.0 ±
3.1, and (H) 92.6 ± 4.4 nm in diameter, respectively. The concentrations of Oﬂx conjugated onto the NPs are determined based on their
conjugation ratios in Table 1. The concentration of AgMUNH2 NPs in (i) of (B−D) and (r) of (F−H) contain the same concentration of NPs as
that in (h) and (q) for each type of NP in (B−D) and (F−H) but without Oﬂx (control experiments to study the eﬀects of AgMUNH2 NPs).

We sampled the cell culture suspension every 6 h and
quantitatively determined the cell concentration by measuring
their OD600 nm (optical density at 600 nm). For the cell

Figure 5E−H: r) for the 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm
NPs, respectively.
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suspensions with nanocarriers or NPs, we subtracted the OD600
nm of the nanocarriers or NPs in the medium (in the absence of
the cells) from the OD600 nm of the cell suspension with the
nanocarriers or NPs to determine the cell concentration,
respectively. We plotted the OD600 nm of the cell suspension
over time and determined 17 h to be the duration that is
needed for the cell grown in the medium alone (control) to
reach conﬂuence and for the cells grown in the medium with
Oﬂx, drug nanocarriers or NPs to reach equilibrium. We then
plotted the OD600 nm of the cell suspension at 17 h versus the
concentration of Oﬂx alone or Oﬂx conjugated with the given
sized drug nanocarriers to determine the MIC of Oﬂx and Oﬂx
nanocarriers for each cell strain.
Plots of the OD600 nm of the cell suspension cultured over 17
h versus the concentration of Oﬂx alone or Oﬂx conjugated
with the given sized drug nanocarriers in Figure 6 show that the
inhibitory eﬀects of Oﬂx highly depend on the dose of Oﬂx, the
sizes of the nanocarriers, and the cellular expression of MexABOprM, as described below.
Control experiments in Figure 6 (a−c) show that the OD600
nm of the cell suspension incubated with each of three diﬀerent
sized AgMUNH2 NPs (absence of Oﬂx, 2.4 ± 0.7, 13.0 ± 3.1,
or 92.6 ± 4.4 nm), which has the same concentration of NPs as
those of the highest concentration of the given sized
nanocarriers, are nearly the same as those cultured in the
medium alone. This result indicates that the AgMUNH2 NPs at
the given concentration do not create signiﬁcant inhibitory
eﬀects on the growth of WT and ΔABM cells.
In contrast, the OD600 nm of the cell suspension incubated
with Oﬂx alone shows a high dose dependent inhibitory eﬀect
of Oﬂx on the growth of WT and ΔABM cells (Figure 6A,B:
d). As the Oﬂx concentration increases, the OD600 nm of the cell
suspension (the number of the cells) decreases. By ﬁtting the
plots, we found that the growth of WT and ΔABM cells was
reduced to half at Oﬂx concentrations of 0.59 ± 0.16 and 0.096
± 0.021 μM (Figure 6A,B: d), respectively. The results show
that the inhibitory eﬀects are highly dependent on the
expression of MexAB-OprM. Here, we deﬁne the MIC of
Oﬂx as the concentration of Oﬂx needed to reduce the growth
of the cells by half. The MIC of Oﬂx for WT (normal
expression of MexAB-OprM) is about 6 times higher than that
for ΔABM (deletion of MexAB-OprM), suggesting that
MexAB-OprM extrudes Oﬂx out of WT cells. Thus, a higher
concentration of Oﬂx is needed to eradicate the WT cells than
that needed for ΔABM cells. In contrast, ΔABM cells do not
possess MexAB-OprM and cannot eﬀectively extrude Oﬂx out
of the cells, which leads to a higher accumulation of Oﬂx inside
the ΔABM cells than that in WT cells. Thus, a lower Oﬂx
concentration is needed to eradicate ΔABM cells compared to
that for WT cells, which agrees with previous reports.55
Plots of OD600 nm of the cell suspension cultured with drug
nanocarriers versus the concentration of Oﬂx conjugated with
each given sized AgMUNH2 NPs (2.4 ± 0.7, 13.0 ± 3.1, or 92.6
± 4.4 nm) also show high dose and MexAB-OprM dependent
inhibitory eﬀects on the growth of WT and ΔABM cells
(Figure 6A,B: e−g). This result suggests that MexAB-OprM
can extrude the drug nanocarriers out of the WT cells, which
reduces the amount of intracellular Oﬂx nanocarriers in WT
cells and leads to a higher MIC for WT cells than that for
ΔABM cells.
Interestingly, the OD600 nm of the cell suspension incubated
with the 2.4 ± 0.7 nm drug nanocarriers with a conjugation
ratio of 8.6 × 102 Oﬂx molecules/NP decrease with Oﬂx

Figure 6. Dose, size, and MexAB-OprM dependent inhibitory eﬀects
of antibiotic nanocarriers (AgMUNH-Oﬂx NPs) against (A) WT and
(B) ΔABM cells. Plots of normalized OD600 nm of cells cultured for 17
h in the modiﬁed LB medium containing (a−c) AgMUNH2 NPs
(absence of Oﬂx, control), (d) Oﬂx alone, and (e−g) Oﬂx conjugated
with the (e) 2.4 ± 0.7, (f) 13.0 ± 3.1, and (g) 92.6 ± 4.4 nm Ag NPs,
respectively. The concentration of AgMUNH2 NPs in (a−c) of (A)
and (B) contain the same concentration of NPs as the nanocarriers
with the highest Oﬂx concentrations in (e−g) for each type of NP in
(A) and (B) but without carrying Oﬂx (control experiments for the
study of eﬀects of NPs). The points are experimental data, and a solid
line was generated by ﬁtting the experimental data with the equation y
= a·e−bx as followings: (A): (d) y = 1.12·e−1.18x, R2 = 0.923; (e) y =
1.07·e−0.764x, R2 = 0.967; (f) y = 1.04·e−1.82x, R2 = 0.964; (g) y = 0.998·
e−6.07x, R2 = 0.997. (B): (d) y = 1.12·e−8.59x, R2 = 0.892; (e) y = 0.984·
e−3.58x, R2 = 0.938; (f) y = 1.13·e−11.35x, R2 = 0.920; (g) y = 0.997·
e−68.82x, R2 = 0.989. Concentrations of Oﬂx (MIC, IC50) for free Oﬂx
and Oﬂx conjugated on a given sized nanocarrier were determined
using the exponential ﬁtting equation at the half of the maximum of
the normalized OD600 nm for each curve, respectively.

concentration less rapidly than those of free Oﬂx and the two
other larger nanocarriers (Figure 6A,B: e), showing MICs of
1.00 ± 0.07 and 0.19 ± 0.05 μM Oﬂx for the WT and ΔABM
cells, which is the highest among the nanocarriers and free Oﬂx
(Table 2).
Notably, the MICs of the 13.0 ± 3.1 nm drug nanocarriers
with a conjugation ratio of 9.6 × 103 Oﬂx molecules/NP are
0.40 ± 0.06 and 0.073 ± 0.012 μM for the WT and ΔABM
cells, respectively (Figure 6A,B: f), which is lower than the
MICs of free Oﬂx and the 2.4 ± 0.7 nm drug nanocarriers.
Furthermore, the MICs of the 92.6 ± 4.4 nm drug nanocarriers
with a conjugation ratio of 6.5 × 105 Oﬂx molecules/NP are
0.11 ± 0.01 and 0.010 ± 0.001 μM for the WT and ΔABM
cells, respectively (Figure 6A,B: g), showing the lowest MIC
and the highest inhibitory eﬀects among the nanocarriers and
free Oﬂx. The results show that the inhibitory eﬀects of Oﬂx are
highly dependent on the dose of Oﬂx, the size of the
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higher binding aﬃnity with the target than those when they are
conjugated on the smaller NPs. The inhibitory eﬀects of the
drug nanocarriers depend on their sizes, but they are not
linearly proportional to their sizes. Interestingly, MexAB-OprM
aﬀects the susceptibility of drug nanocarriers in a sizedependent fashion. For example, the ratios of the MIC of
WT to ΔABM cells for free Oﬂx and Oﬂx conjugated on the 2.4
± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm drug nanocarriers are 6.1,
5.3, 5.5, and 11, respectively, as shown in Figure 6 and Table 2.
Notably, for WT cells, the net gain in the amount of
accumulated intracellular nanocarriers is determined by
subtracting the amount of nanocarriers extruded out of the
cells by MexAB-OprM from the amount of nanocarriers that
entered the cells. Note that ΔABM cells were constructed by
the deletion of mexAB-oprM in WT cells. Thus, the amount of
the nanocarriers that entered the ΔABM cells should be the
same as those entered the WT cells. If the extrusion of
nanocarriers by MexAB-OprM was size-independent, then the
ratio of the MICs of WT to ΔABM cells for each sized
nanocarrier should be the same, respectively. However, they
were not. The MIC of the largest nanocarriers (92.6 ± 4.4 nm)
against ΔABM is 19 times lower than that of the smallest
nanocarriers (2.4 ± 0.7 nm), whereas the MIC of the largest
nanocarriers (92.6 ± 4.4 nm) against WT is 9 times lower than
that of the smallest nanocarrier (2.4 ± 0.7 nm). A plausible
explanation for this ﬁnding is the size-dependent eﬄux function
of MexAB-OprM, and MexAB-OprM could extrude Oﬂx
molecules on the largest nanocarriers out of the WT cells,
which could aﬀect the MIC of the largest nanocarriers the most.
For example, when the cell extrudes a largest nanocarrier, it can
reduce the intracellular Oﬂx 756 times more than extrusion of a
smallest carrier. Because the inhibitory eﬀects of the largest
nanocarriers (92.6 ± 4.4 nm) are much higher than the two
other sized nanocarriers and free Oﬂx, we still observed the
lowest MIC of the largest nanocarriers against the WT cells,
despite its extrusion by MexAB-OprM aﬀecting the accumulation of intracellular Oﬂx the most. These interesting ﬁndings
further demonstrate that the combination of several factors
(multivalence, pharmacodynamics, and pharmacokinetics, e.g.,
distribution and eﬄux of Oﬂx and Oﬂx nanocarriers) aﬀects the
inhibitory eﬀects of Oﬂx against the cells. This study
demonstrates the possibility of designing antibiotic nanocarriers
that could potentially generate the most potent eﬀect against
highly infectious bacterial cells, such as P. aeruginosa.

Table 2. Dependence of the MIC of Oﬂx on the Sizes of the
Nanocarriers and Expression of MexAB-OprM for Two
Strains of P. aeruginosa (WT and ΔABM)
MIC50 of Oﬂx (μM)a
samples
free Oﬂx alone
nanocarriers (2.4 ± 0.7 nm)
nanocarriers (13.0 ± 3.1 nm)
nanocarriers (92.6 ± 4.4 nm)

WT
0.59
1.00
0.40
0.11

±
±
±
±

0.16
0.07
0.06
0.01

ΔABM
0.096
0.19
0.073
0.010

±
±
±
±

0.021
0.05
0.012
0.001

The MIC of Oﬂx for each sample was determined by ﬁtting the
experimental data with the exponential decay equation (y = a·e−bx,
inhibitory eﬀects upon exponential cell growth) to determine the
parameters (a and b) of a ﬁtting equation with a regression. The
equation was then used to determine the concentration of Oﬂx at
which the cell growth was inhibited to half of the cell growth of the
blank control experiment, as described in the caption of Figure 6.
a

nanocarrier, and the cellular expression of MexAB-OprM. For
the same amount of Oﬂx against WT and ΔABM cells, the Oﬂx
molecules carried and delivered by the largest NPs (92.6 ± 4.4
nm) are the most potent, followed by the 13.0 ± 3.1 nm
nanocarriers, free Oﬂx, and the 2.4 ± 0.7 nm nanocarriers
(Table 2).
For ΔABM cells (absence of MexAB-OprM), the MICs of
Oﬂx conjugated on the 13.0 ± 3.1 and 92.6 ± 4.4 nm
nanocarriers are 2.6 and 19 times lower than that of Oﬂx
conjugated on the smallest nanocarriers (2.4 ± 0.7 nm). In
other words, the same amount of Oﬂx is the most potent when
it is delivered into the cells using the largest nanocarriers (92.6
± 4.4 nm) and vice versa, suggesting that densely packed Oﬂx
on larger nanocarriers could oﬀer a higher binding aﬃnity with
the target (multivalent eﬀect) and a higher local drug dose for
binding with the target compared to those of Oﬂx molecules
conjugated on the smaller nanocarriers. Interestingly, the MIC
of free Oﬂx against the ΔABM cells is only half of the MIC of
Oﬂx on the 2.4 ± 0.7 nm nanocarriers, but it is nearly the same
as that of Oﬂx on the 13.0 ± 3.1 nm nanocarriers and almost 10
times higher than that of Oﬂx on the 92.6 ± 4.4 nm
nanocarriers. In other words, the inhibitory eﬀects of the drug
nanocarriers depend on their sizes, but they are not linearly
proportional to their sizes, which suggests that the distribution
of the same amount of the drug throughout the cells
(pharmacodynamics) versus the localization of the same drug
dose on individual nanocarriers (high aﬃnity) could play roles
that trade oﬀ with regard to their inhibitory eﬀects. Free Oﬂx
and smaller nanocarriers diﬀuse faster and the Oﬂx could be
better distributed inside the cells than Oﬂx on the larger
nanocarriers. In contrast, the larger nanocarriers oﬀer a higher
local drug dose and higher aﬃnity with the target than the
smaller nanocarriers. The combination of both factors creates
the optimal susceptibility of the nanocarriers against the cells.
This result suggests that a critical size of the nanocarriers could
be needed to generate optimal potency against the bacterial
cells.
For WT cells, the MICs of Oﬂx attached onto the 13.0 ± 3.1
and 92.6 ± 4.4 nm NPs are 2.5 and 9.1 times lower than that of
Oﬂx on the smallest nanocarriers (2.4 ± 0.7 nm), respectively.
Similar to those observed in using ΔABM cells, the same
amount of Oﬂx is the most potent when it is delivered into the
WT cells using the largest nanocarriers (92.6 ± 4.4 nm) and
vice versa, further suggesting that densely packed Oﬂx on the
larger nanocarriers could oﬀer a higher local concentration and

■

SUMMARY
We have synthesized and characterized three diﬀerent sized
antibiotic nanocarriers (AgMUNH-Oﬂx NPs) by functionalizing three diﬀerent sized Ag NPs (2.4 ± 0.7, 13.0 ± 3.1, and 92.6
± 4.4 nm) with a monolayer of AUT to prepare AgMUNH2
NPs, followed by covalently linking them with antibiotic (Oﬂx)
molecules. We successfully developed a modiﬁed LB medium
to culture P. aeruginosa (WT and ΔABM) that allows the
nanocarriers (AgMUNH-Oﬂx NPs) and AgMUNH2 NPs at the
desired concentration to be stable (non-aggregated) throughout the duration of the cell culture experiment. We studied the
dependence of the inhibitory eﬀects of free Oﬂx and Oﬂx
covalently attached onto the surface of nanocarriers on the dose
of Oﬂx, the sizes of the nanocarriers, and the cellular expression
of MexAB-OprM. We found that the inhibitory eﬀects of Oﬂx
highly depend on the dose of Oﬂx, the size of the nanocarrier,
and the cellular expression of MexAB-OprM. Interestingly, the
largest nanocarriers (92.6 ± 4.4 nm) have the lowest MICs of
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(MaxQ 5000, 200 rpm, 37 °C) for another 8 h. We followed
the growth of the cells in each respective medium over time and
characterized the cell growth curves by measuring the OD600 nm
of the cell suspensions in the medium every 30 min over 8 h of
cell culture. We studied the viability of the cultured cells by the
end of culture at single cell resolution using LIVE/DEAD
BacLight viability and counting assay.57 The cells in the
medium were imaged in a microchamber using dark-ﬁeld
optical microscopy and epiﬂuorescence microscopy.33,36,40,41,50
The green ﬂuorescence cells (peak wavelength of the
ﬂuorescence spectra of SYTO9, λmax = 520 nm) and red
ﬂuorescence cells (peak wavelength of the ﬂuorescence spectra
of propidium iodide, λmax = 610 nm) were used to determine
live and dead cells, respectively.57
By the end of the cell culture, we harvested the cells using
centrifugation (Beckman JA-14, 7500 rpm) and rinsed them
with PBS buﬀer (0.5 mM phosphate buﬀer, 1.5 mM NaCl, pH
7.0) three times via centrifugation. We then suspended the cells
in PBS buﬀer and adjusted the cell suspension concentration to
OD600 nm = 0.1.36,40,41,50,52,53 We characterized the eﬄux
function of the MexAB-OprM membrane transporter of live
cells cultured in each medium by continuously measuring the
ﬂuorescence intensity of the cell suspension (OD600 nm = 0.1)
containing 10 μM EtBr in real time (3 s time interval) for 2 h
using a ﬂuorescence spectrometer (PerkinElmer LS50B) with
the excitation and emission wavelengths at 465 and 600 nm,
respectively.50,52,53
Synthesis and Characterization of Ag NPs. We had
synthesized, puriﬁed, and characterized three diﬀerent sized Ag
NPs with diameters of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm,
as we reported previously.32,37,38,46−48,58 Brieﬂy, we synthesized
Ag NPs with a diameter of 2.4 ± 0.7 nm by adding NaBH4 (150
μL, 100 mM) into a stirring mixture (42.3 mL) of silver nitrate
(0.11 mM), sodium citrate (1.91 mM), PVP (0.052 mM), and
hydrogen peroxide (25.0 mM) that was freshly prepared using
nanopure water.38 We stirred the solution at room temperature
for another 3 h and ﬁltered the solution using 0.2 μm
membrane ﬁlters. We prepared Ag NPs with a diameter of 13.0
± 3.1 nm by rapidly adding ice-cold AgClO4 (2.5 mL of 10
mM) into a stirring ice-cold mixture (247.5 mL) of sodium
citrate (3 mM) and NaBH4 (10 mM).34,39 We stirred the
solution at room temperature for 4 h and ﬁltered it using a 0.2
μm ﬁlter. We synthesized 92.6 ± 4.4 nm Ag NPs by adding
sodium citrate (10 mL, 34 mM) into a reﬂuxing (100 °C)
aqueous solution of 3.98 mM AgNO3 (500 mL).32,59 We stirred
the mixture at 325 rpm for 35 min and cooled the solution to
room temperature. We then added additional 2.5 mM sodium
citrate as a stabilizer into the solution and ﬁltered the solution
using a 0.2 μm ﬁlter.
We puriﬁed each NP solution by thoroughly washing the
NPs three times with DI water using centrifugation
immediately after the synthesis. We characterized the NP
concentration, LSPR images and spectra, and sizes of single
NPs using UV−vis spectroscopy (Hitachi U-2010), dark-ﬁeld
optical microscopy and spectroscopy (DFOMS), highresolution transmission electron microscopy (HRTEM)
(JEOL, JEM-2100F), and dynamic light scattering (DLS)
(Nicomp 380ZLS particle sizing system), respectively. We have
fully described our DFOMS approach in our previous
studies.33,34,36−41,44,52,60,61 In this study, the DFOMS system
is equipped with a dark-ﬁeld optical microscope with a darkﬁeld condenser (oil 1.43−1.20, Nikon) and a 100× objective
(Nikon Plan ﬂuor 100× oil, iris, SL. N.A. 0.5−1.3, W.D. 0.20

0.11 ± 0.01 and 0.010 ± 0.001 μM Oﬂx against WT and
ΔABM cells, following by the 13.0 ± 3.1 nm nanocarriers and
free Oﬂx, whereas the smallest nanocarriers (2.4 ± 0.7 nm)
have the highest MICs of 1.00 ± 0.07 and 0.19 ± 0.05 μM Olfx
against WT and ΔABM cells, respectively. The results show
that the largest nanocarriers exhibit the highest bactericidal
eﬀects, whereas the smallest nanocarriers show the lowest
bactericidal eﬀects, demonstrating that the same amount of
Oﬂx creates a higher bactericidal eﬀect when they are carried
and delivered by larger NPs. These ﬁndings suggest that the
close-packed Oﬂx molecules on the NPs (multivalence) could
enhance their binding aﬃnity with the target and oﬀer a higher
payload to increase the local drug dose and potency. Notably,
the MIC of the largest nanocarriers (92.6 ± 4.4 nm) for ΔABM
is 19 times lower than that for the smallest nanocarriers (2.4 ±
0.7 nm), whereas the MIC of the largest nanocarriers (92.6 ±
4.4 nm) for WT is 9 times lower than that of the smallest
nanocarriers (2.4 ± 0.7 nm). The results suggest that MexABOprM can eﬀectively extrude such large nanocarriers out of
WT cells and that the extrusion of the larger nanocarriers can
aﬀect the inhibitory eﬀect of Oﬂx more signiﬁcantly than the
smaller nanocarriers due to the larger payload of Oﬂx on the
larger nanocarriers. In other words, MexAB-OprM could be
more eﬃcient at protecting bacteria from larger nanocarriers
than small nanocarriers. Interestingly, although the inhibitory
eﬀects of the drug nanocarriers depend on their sizes, they are
not linearly proportional to their sizes, which suggests that the
inhibitory eﬀects of Oﬂx depend not only on multivalent local
targeting eﬀects but also on its intracellular distribution
(pharmacodynamics) and extrusion by the transporter. Thus,
an optimal size of the nanocarriers would be needed to generate
optimal inhibitory eﬀects. These interesting ﬁndings further
demonstrate the possibility of designing antibiotic nanocarriers
that could potentially evade MDR and generate the most
potent eﬀect against highly infectious bacterial cells, such as P.
aeruginosa.

■

MATERIALS AND METHODS
Reagents and Supplies. We purchased silver perchlorate
monohydrate (99%, Alfa Aesar), sodium citrate dihydrate (99%,
Sigma), sodium borohydride (98%, Sigma), hydrogen peroxide
(30%, Sigma), polyvinylpyrrolidone (PVP, Sigma), 2-mercaptoethanol (99%, Sigma), 11-amino-1-undecanethiol hydrochloride (AUT, 99%, Sigma), 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (EDC, 99%, Pierce), Nhydroxysulfosuccinimide (sulfo-NHS, 98.5%, Pierce), oﬂoxacin
(≥98%, Oﬂx, Enzo), L-broth (LB) powder (Sigma), and the
LIVE/DEAD BacLight viability and counting assay (Invitrogen) and used them as received. We used nanopure deionized
(DI) water (18 MΩ water, Barnstead) to prepare commonly
used standard LB medium (1% tryptone, 0.5% yeast extract,
and 0.5% NaCl in DI water, pH = 7.2) and our modiﬁed LB
medium (1% tryptone, 0.5% yeast extract, and 0.1% NaCl in DI
water, pH = 7.2)
Cell Lines, Cell Culture Medium, Cell Culture, and
Characterization. Three strains of Gram-negative bacterial
cells (P. aeruginosa), WT (PA04290, normal expression of
MexAB-OprM), nalB-1 (overexpression mutant of MexABOprM), and ΔABM (deletion of MexAB-OprM), were
generously provided by Dr. Hiroshi Yoneyama and used for
this study.51,56 We ﬁrst precultured the cells in commonly used
standard LB medium for 12 h. We then cultured the cells using
either standard LB medium or modiﬁed LB medium in a shaker
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conjugation ratio of Oﬂx molecules to NPs for each size of drug
nanocarrier.
Stability of Drug Nanocarriers (AgMUNH-Oﬂx NPs) in
Cell Culture Medium. We characterized the stability (nonaggregation) of AgMUNH-Oﬂx NPs in the commonly used
standard LB medium (1% tryptone, 0.5% yeast extract, and
0.5% NaCl in DI water, pH = 7.2) and the modiﬁed medium
(1% tryptone, 0.5% yeast extract, and 0.1% NaCl in DI water,
pH = 7.2) over 24 h using UV−vis absorption spectroscopy.
We found that the nanocarriers with Ag NP diameters of 2.4 ±
0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm at the desired concentration
(6.0 nM, 0.8 nM and 7 pM) were stable (non-aggregated) in
the modiﬁed medium over 24 h, but they are unstable
(aggregated) in the standard medium, respectively.
Inhibitory Eﬀects of Drug Nanocarriers (AgMUNHOﬂx NPs). We pre-cultured the cells (WT or ΔABM) in the
standard LB medium overnight. We then cultured the cells in
the modiﬁed LB medium (4 mL) containing a dilution series of
Oﬂx alone, a given sized drug nanocarrier (AgMUNH-Oﬂx
NPs), and AgMUNH 2 NPs (control experiments) by
inoculating 104 pre-cultured cells into the medium and
vigorously shaking the solution (200 rpm, 37 °C) over 18 h.
The dilution series contains 0, 0.20, 0.40, 0.60, 0.80, 1.08,
1.62, and 2.16 μM free Oﬂx or Oﬂx conjugated with the NPs
(AgMUNH-Oﬂx NPs) for WT cells, which is correlated with
the concentration of the nanocarriers (NP concentration) as
follows: (i) 0.23, 0.463, 0.695, 0.917, 1.25, 1.88, and 2.50 nM
for the 2.4 ± 0.7 nm NPs with a conjugation ratio of 8.6 × 102
Oﬂx molecules per NP; (ii) 2.12 × 10−2, 4.24 × 10−2, 6.36 ×
10−2, 8.48 × 10−2, 0.114, 0.172, and 0.229 nM for the 13.0 ±
3.1 nm NPs with a conjugation ratio of 9.4 × 103 Oﬂx
molecules per NP; and (iii) 0.309, 0.618, 0.926, 1.24, 1.67, 2.50,
and 3.34 pM for the 92.6 ± 4.4 nm NPs with a conjugation
ratio of 6.5 × 105 Oﬂx molecules per NP, respectively. The
control experiments include the modiﬁed LB medium alone
(absence of cells) and WT cells cultured under the same
conditions and at the same time in the medium containing 2.50
nM, 0.229 nM, or 3.34 pM AgMUNH2 NPs (in the absence of
Oﬂx) for the 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm Ag NPs,
respectively.
The dilution series contains 0, 0.020, 0.040, 0.060, 0.080,
0.11, 0.14, 0.28 μM free Oﬂx or Oﬂx conjugated with the NPs
(AgMUNH-Oﬂx NPs) for ΔABM cells, which is correlated
with the concentration of the nanocarrier (NP concentration)
as follows: (i) 2.32 × 10−2, 4.63 × 10−2, 6.95 × 10−2, 9.27 ×
10−2, 0.127, 0.162, and 0.324 nM for the 2.4 ± 0.7 nm NPs
with a conjugation ratio of 8.6 × 102 Oﬂx molecules per NP;
(ii) 2.12 × 10−3, 4.24 × 10−3, 6.36 × 10−3, 8.48 × 10−3, 1.48 ×
10−2, and 2.97 × 10−2 nM for the 13.0 ± 3.1 nm NPs with a
conjugation ratio of 9.4 × 103 Oﬂx molecules per NP; and (iii)
3.09 × 10−2, 6.18 × 10−2, 9.26 × 10−2, 0.124, 0.170, 0.216, and
0.432 pM for the 92.6 ± 4.4 nm NPs with a conjugation ratio of
6.5 × 105 Oﬂx molecules per NP. The control experiments
included the modiﬁed LB medium alone (absence of cells) and
the ΔABM cells cultured under the same conditions and at the
same time in the medium containing 0.324 nM, 2.97 × 10−2
nM, or 0.432 pM AgMUNH2 NPs (in the absence of Oﬂx) for
the 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm Ag NPs,
respectively.
We sampled the cell culture suspension every 6 h and
quantitatively determined the cell concentration by measuring
their OD600 nm in a 96-well plate using a plate reader (BioTek
Synergy HT) equipped with an UV−vis absorption spectral

mm), a CCD camera (Micromax, Roper Scientiﬁc), and a
multispectral imaging system (Nuance, CRI).38,60
Synthesis and Characterization of Drug Nanocarriers
(AgMUNH-Oﬂx NPs). We added AUT (1 mL, 100 mM, in
ethanol) into the freshly prepared Ag NPs (100 mL, 50 nM, 3.3
nM, and 30 pM) of three diﬀerent sizes (2.4 ± 0.7, 13.0 ± 3.1
and 92.6 ± 4.4 nm), respectively. We stirred the mixtures for 24
h to attach AUT onto the surface of the NPs via the interaction
of thiol groups with the NPs to prepare functional AgMUNH2
NPs (Figure 2). We washed the AgMUNH2 NPs thoroughly
three times with nanopure water to remove excess AUT using
centrifugation (Beckman Optima L90k, 4 °C). After each
washing and resuspension step, we immediately characterized
the concentrations, optical properties, and sizes of each
AgMUNH 2 NP solution using UV−vis spectroscopy,
DFOMS, and DLS, respectively. Note that the AgMUNH2
NPs were suspended in DI water for storage and only
suspended in the respective buﬀer immediately before the
experiment.
We suspended half of the puriﬁed AgMUNH2 NP solution
(50 mL) in PBS buﬀer (pH 7.0) immediately before control
experiments. We suspended the other half of the AgMUNH2
NP solution (50 mL) in MES buﬀer (50 mM, pH 5.0)
immediately before conjugating these NPs with Oﬂx. We
conjugated the amine groups of each size of AgMUNH2 NPs
(50 mL) with the carboxyl group of Oﬂx via peptide bonds
using a two-step method with EDC and sulfo-NHS as
mediators (Figure 2), as described in the following. We ﬁrst
dissolved Oﬂx in 0.5 M HCl (1 mL) and then diluted it using
MES buﬀer (pH 5.0). We added EDC (100 μL, 100 mM) and
sulfo-NHS (100 μL, 500 mM) into the Oﬂx solution (3 mL, 50
mM) and stirred it at room temperature for 40 min to form
Oﬂx−sulfo-NHS esters. We added 2-mercaptoethanol to
quench the excess EDC. We added the Oﬂx−sulfo-NHS esters
to the AgMUNH2 NPs in MES buﬀer (pH 5.0) and mixed the
solution using a rotary shaker at room temperature for 3 h to
synthesize the AgMUNH-Oﬂx NPs (nanocarriers).
We puriﬁed the drug nanocarriers (AgMUNH-Oﬂx NPs) by
washing them with DI water three times and stored them at 4
°C for future use. After each washing step, we immediately
characterized the concentrations, optical properties, and sizes of
the AgMUNH2 NPs using UV−vis spectroscopy, DFOMS, and
DLS, respectively. We measured the UV−vis absorbance
spectra of various concentrations of nanocarriers (AgMUNHOﬂx NPs) and plotted the peak absorbance of the nanocarriers
versus their concentrations to construct a calibration curve and
determine their molar absorptivity.
We measured the UV−vis absorbance spectra of various
concentrations of Oﬂx alone (absence of NPs) in solution and
plotted the peak absorbance at 288 nm versus Oﬂx
concentration to construct a calibration curve and determine
its molar absorptivity (ε288nm = 7.8 × 103 M−1 cm−1 and ε330nm
= 2.4 × 103 M−1 cm−1). We subtracted the UV−vis absorption
spectrum of the AgMUNH2 NPs from that of AgMUNH-Oﬂx
NPs of the same size and concentration to obtain the UV−vis
absorption spectrum of Oﬂx conjugated with the AgMUNH2
NPs, and we used the molar absorptivity of Oﬂx to determine
its concentration. We also determined the NP concentration
based on the peak absorbance of the plasmonic absorption
spectra of the NPs. By dividing the concentration of Oﬂx with
concentration of NPs in the same AgMUNH-Oﬂx NP solution
using UV−vis absorption spectroscopy, we determined the
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detector. We plotted the OD600 nm of the cell suspension over
time to determine the duration (17 h) that is needed for the
cells to reach conﬂuence. We used the OD600 nm of each cell
suspension at 17 h to determine their inhibitory eﬀects as
described in the following.
We normalized the OD600 nm of each cell suspension with the
maximum OD600 nm (the cells cultured in medium alone, blank
control) among the dilution series of the cell suspensions for
each type of sample (e.g., free Oﬂx and each sized nanocarrier).
We then plotted the normalized OD600 nm of the cell suspension
versus the concentration of free Oﬂx (Oﬂx alone) or the
concentration of Oﬂx attached onto a given sized drug
nanocarrier to determine the MIC of Oﬂx. Each experiment
was repeated three times. For each sample, the average of three
experimental measurements with a standard deviation of the
normalized OD600 nm of each cell suspension (points in Figure
6) was ﬁtted using the exponential decay (y = a·e−bx, inhibitory
eﬀects upon the exponential cell growth) to determine the
parameters (a, b) of the equation with the highest possible
regression. The equation was then used to determine the MIC
(the concentration of Oﬂx at which the cell growth was
inhibited to half of the cell growth of the blank control
experiment), as described in the caption of Figure 6. For
example, the points in Figure 6 are experimental data, and a
solid line is generated by ﬁtting the experimental data with the
equation y = a·e−bx as follows: (A): (d) y = 1.12·e−1.18x, R2 =
0.923; (e) y = 1.07·e−0.764x, R2 = 0.967; (f) y = 1.04·e−1.82x, R2 =
0.964; (g) y = 0.998·e−6.07x, R2 = 0.997. (B): (d) y = 1.12·e−8.59x,
R2 = 0.892; (e) y = 0.984·e−3.58x, R2 = 0.938; (f) y = 1.13·
e−11.35x, R2 = 0.920; (g) y = 0.997·e−68.82x, R2 = 0.989.
Parameters “a” and “b” in the equation for each sample were
determined based on the best ﬁt (i.e., the highest regression
with the lowest error). Concentrations of Oﬂx (MIC, IC50) for
free Oﬂx and Oﬂx conjugated with a given sized nanocarrier
were determined using the exponential ﬁtting equation at half
of the maximum normalized OD600 nm for each curve. As a
control experiment, we also plotted the normalized OD600 nm of
the cell suspension at 17 h versus the concentration of
AgMUNH2 NPs (absence of Oﬂx) that was the same as the
highest concentration of the given nanocarrier for each cell
strain.
Data Analysis and Statistics. We characterized the sizes
and shapes of Ag NPs using TEM, and we acquired LSPR
spectra of single Ag NPs, AgMUNH2 NPs, and AgMUNH-Oﬂx
NPs using DFOMS. For each size and each type of the NP, we
imaged at least 100 NPs for each measurement, and we
repeated each experiment three times. Thus, a minimum of 300
NPs were characterized using TEM and DFOMS. All
experiments, including the study of the stability of the NPs in
the medium, cell growth curves, and MICs, were repeated three
times. We used the average of three measurements with
standard deviations for each study as described above.
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